CDW is in a powerful recovery uptrend that has fully reversed an earlier breakdown. The stock's 1-year price change is a modest +4.18%, but that headline masks a violent round trip: shares collapsed from roughly $137 in early May to a 52-week low of $97.12, then rallied to the current $165.11, which sits at approximately 99.4% of the 52-week range (low $97.12 to high $166.15). Trading essentially at the top of its annual range signals strong momentum but also raises overextension risk, particularly given the stock is now up 23.99% year-to-date versus just 11.45% for the S&P 500. The maximum drawdown of -39.66% over the period underscores how sharp the prior decline was and how complete the subsequent recovery has been.

Short-term momentum is decisively positive and accelerating. The stock is up 12.97% over the past month and 23.38% over three months, with a 6-month gain of 22.01%, meaning the bulk of the move has been concentrated in the recent leg higher. Relative strength confirms genuine outperformance rather than beta-driven drift: CDW has beaten the S&P 500 by 13.99 percentage points over one month and 20.53 points over three months, even as its 1-year relative strength remains negative at -8.95 points—evidence that the recent surge is repairing, but has not yet erased, a year of underperformance. The one-month trend (+12.97%) is now strongly at odds with the trailing 1-year figure (+4.18%), a divergence that typically signals either the early stage of a durable trend reversal or a mean-reversion rally vulnerable to profit-taking; the fact that the move is being confirmed by relative strength leans toward the former, though the pace argues for caution.

Key technical levels are well defined. Resistance sits at the 52-week high of $166.15, just 0.6% above the current $165.11—a breakout above that level on volume would confirm the recovery and likely invite momentum buyers, while repeated failure there could mark a double-top-style stall. Support is anchored at the $97.12 52-week low, with intermediate support likely in the $128–$135 zone where the stock consolidated in late September and early October 2026. With a beta of 0.941, CDW is slightly less volatile than the market, which tempers position-sizing risk somewhat, but the -39.66% max drawdown demonstrates that idiosyncratic margin and earnings shocks can overwhelm that low beta; the short ratio of 5.95 days also implies meaningful short interest that could fuel further upside on a breakout or amplify a reversal.

Revenue is reaccelerating after a soft patch. Second-quarter 2026 revenue reached $6.572 billion, up 9.97% year over year from $5.977 billion in Q2 2025, and up sequentially from $5.680 billion in Q1 2026. The multi-quarter trend is clearly improving: year-over-year growth was roughly 9.2% in Q1 2026 ($5.680 billion vs. $5.199 billion) and has now compounded into a two-quarter run of high-single-digit expansion after a period of flattish results in late 2025. Segment data shows the mix is hardware-heavy—total hardware of $4.905 billion dwarfs software at $1.114 billion, services at $521 million, and other at $32 million—meaning the recovery is being driven by lower-margin product volume, which is precisely why the growth is not translating into proportionally better earnings.

Profitability is the central concern. The company remains solidly profitable—Q2 2026 net income of $274.4 million on a 4.18% net margin—but margins are compressing: gross margin fell to 20.08% in Q2 2026 from 22.76% in Q4 2025 and 21.88% in Q3 2025, while operating margin slipped to 6.52% from 7.82% in Q4 2025. The trailing gross margin of 21.73% and operating margin of 7.38% reflect a business where hardware mix and competitive pricing are eroding the spread; net income of $274.4 million was actually down from $291.0 million in Q3 2025 despite higher revenue, a classic sign of margin-led earnings pressure. For a distribution-model reseller, thin gross margins are normal, but the direction of travel—roughly 270 basis points of gross-margin erosion in two quarters—is what drove the May selloff and remains the key swing factor for the investment case.

Balance sheet and cash flow are adequate but leveraged. Debt-to-equity stands at 2.43x with a current ratio of 1.18, and TTM free cash flow is $1.109 billion against a $17.9 billion market cap—a modest FCF yield of roughly 6.2%. ROE is a striking 40.9%, though this is flattered by the leveraged capital structure and a 6.15x equity multiplier rather than by exceptional returns on assets (ROA is just 6.59%). Quarterly free cash flow has been volatile—$165.8 million in Q2 2026 versus $395.9 million in Q4 2025—driven by working-capital swings (a $1.054 billion receivables build in Q2), and the company continues to return capital aggressively with $544.7 million of buybacks and $160.9 million of dividends in Q2 alone. The combination of high leverage, working-capital intensity, and shareholder returns means CDW depends on consistent operating cash generation to fund growth; any sustained margin deterioration would pressure both the dividend coverage and the buyback.